Effect of SiO2 nanoparticles on drought resistance in hawthorn seedlings

Drought is a significant factor limiting crop production in arid regions while hawthorns (Crataegus sp.) are an important component of such region’s forests. Therefore, treatments that increase hawthorn drought resistance may also increase transplanting success. Thus, the physiological and biochemical responses of hawthorn seedlings to a factorial combination of different concentrations of silica nanoparticles (SNPs at 0, 10, 50 and 100 mg L-1) and three soil moisture treatments (without stress, moderate stress and severe stress) were investigated. Seedlings were irrigated with one of the four concentrations of SNPs for 45 days before exposing them to drought stress. Photosynthesis parameters, malondialdehyde (MDA), relative water content (RWC ), membrane electrolyte leakage (ELI) as well as chlorophyll, carotenoid, carbohydrate and proline content were determined. At the end of the experiment, positive effects by SNP pre-treatment on physiological indexes were observed during drought stress. Under drought conditions, the effect of SNPs on photosynthetic rate and stomatal conductance was evident. Although the SNPs increased plant biomass, xylem water potential and MDA content, especially under drought conditions, RWC and ELI were not affected by the SNP pre-treatments. Seedlings pre-treated with SNPs had a decreased carbohydrate and proline content under all water regimes, but especially so under drought. Total chlorophyll content and carotenoid content did not change among the treatments. Generally, the findings imply that SNPs play a positive role in maintaining critical physiological and biochemical functions in hawthorn seedlings under drought stress conditions. However, more studies are needed before the physiological and biochemical basis of induced drought resistance can be determined

Oxidative impairment of plasma and skeletal muscle sarcoplasmic reticulum in rats with adjuvant arthritis - effects of pyridoindole antioxidants

OBJECTIVES: To study possible oxidation of proteins and lipids in plasma and sarcoplasmic reticulum (SR) from skeletal muscles and to assess the effects of pyridoindole antioxidants in rats with adjuvant arthritis (AA) and to analyze modulation of Ca-ATPase activity from SR (SERCA). METHODS: SR was isolated by ultracentrifugation, protein carbonyls in plasma and SR were determined by ELISA. Lipid peroxidation was analyzed by TBARS determination and by mass spectrometry. ATPase activity of SERCA was measured by NADH-coupled enzyme assay. Tryptophan fluorescence was used to analyze conformational alterations. RESULTS: Increase of protein carbonyls and lipid peroxidation was observed in plasma of rats with adjuvant arthritis. Pyridoindole antioxidant stobadine and its methylated derivative SMe1 decreased protein carbonyl formation in plasma, effect of stobadine was significant. Lipid peroxidation of plasma was without any effect of pyridoindole derivatives. Neither protein oxidation nor lipid peroxidation was identified in SR from AA rats. SERCA activity from AA rats increased significantly, stobadine and SMe1 diminished enzyme activity. Ratio of tryptophan fluorescence intensity in SR of AA rats increased and was not influenced by antioxidants. CONCLUSION: Plasma proteins and lipids were oxidatively injured in rats with AA; antioxidants exerted protection only with respect to proteins. In SR, SERCA activity was altered, apparently induced by its conformational changes, as supported by study of tryptophan fluorescence. Stobadine and SMe1 induced a decrease of SERCA activity, elevated in AA rats, but they did not affect conformational changes associated with tryptophan fluorescence

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)

Purpose: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are few studies exploring their use in DME in real-world settings. Methods: POLARIS was a noninterventional, multicentre study to monitor 12-month outcomes in patients starting ranibizumab treatment in routine practices. The primary outcome was mean change in visual acuity (VA) from baseline to month 12 (last observation carried forward approach). Other outcomes included mean change in central retinal thickness (CRT) and resource utilization. Visual acuity (VA) outcomes were also stratified by country, baseline visual acuity score (VAS), sex, age and injection frequency. Results: Outcomes were analysed from all treated patients (n = 804) and from first-year completers (patients who had a visual acuity assessment at 12 months; n = 568). The mean (SD) baseline VAS was 59.4 (15.9) letters, and the mean change in visual acuity was 4.4 letters (95% confidence interval: 3.3–5.4) at month 12 (study eye; first-year completers). The mean number of injections (study eye) was 4.9, and the mean number of all visits (any eye) was 10 (58% were injection visits) over 12 months (first-year completers). The mean (SD) baseline CRT was 410.6 (128.8) μm, and the mean change in CRT was −115.2 μm at month 12 (study eye; first-year completers). Visual acuity (VA) outcomes were generally comparable across most countries and subgroups and were greatest in patients with the lowest baseline VAS (≤60 letters). Conclusion: POLARIS showed that real-world outcomes in DME patients starting treatment with ranibizumab were lower than those observed in clinical studies, in spite of extensive monitoring. © 2018 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation